Isolation of Chlamydophila pneumoniae from atheromas of the carotid artery and their antibiotics susceptibility profile

Enfermedades Infecciosas y Microbiologia Clinica

Volumn 24, Issue 2, 2006, Pages 81-85

  Cuffini, Cecilia ^a,e   Guzmán, Luis Alberto ^b   Villegas, Néstor ^c   Alonso, Carlos Eduardo ^a   Martínez Riera, Leandro ^b   Rodríguez Fermepín, Marcelo ^d   Entrocassi, Andrea Carolina ^d   Adamo, María Pilar ^a   Pedranti, Mauro ^a   Zapata, Marta ^a  

^a FACULTAD DE CIENCIAS MÉDICAS   (Argentina)

^b Hospital Allende   (Mexico)

^c HOSPITAL PRIVADO   (Argentina)

^d UNIVERSIDAD DE BUENOS AIRES   (Argentina)

^e NONE   (Argentina)

Author keywords

Antibiotic susceptibility; Atherosclerosis; C. Pneumoniae

Indexed keywords

AZITHROMYCIN; PENICILLIN G; ROXITHROMYCIN;

ANTIBIOTIC SENSITIVITY; ARTERY DISEASE; ARTERY WALL; ARTICLE; ATHEROMA; ATHEROSCLEROSIS; BACTERIUM ISOLATION; CAROTID ARTERY DISEASE; CAROTID ENDARTERECTOMY; CHLAMYDOPHILA PNEUMONIAE; CHRONIC INFLAMMATION; DIAGNOSTIC TEST; HIGH RISK PATIENT; HUMAN; HUMAN TISSUE; POLYMERASE CHAIN REACTION; SAMPLING; TRANSMISSION ELECTRON MICROSCOPY;

EID: 33645389506     PISSN: 0213005X     EISSN: None     Source Type: Journal    
DOI: 10.1157/13085013     Document Type: Article

References (33)

1. Stoyioglou A, Jaff M. Medical treatment of peripheral arterial disease: A comprehensive review. J Vasc Interv Radiol. 2004;15:1197-207.
2. Grayston JT, Kuo CC, Wang SP, Altman J. A new Chlamydia psittaci strain, TWAR, isolated in acute respiratory tract infections. N Engl J Med. 1986;315:161-8.
3. Grayston JT. Chlamydia pneumoniae (TWAR) infections in children. Pediatr Infect Dis J. 1994;13:675-85.
4. Saikku P, Leinonen M, Mattila K, Nieminen MS, Makela PH, Huttunen JK, et al. Serological evidence of an association of a novel Chlamydia, TWAR, with chronic coronary heart disease and acute myocardial infarction. Lancet. 1988;2:983-6.
5. Wong YK, Dawkins KD, Ward ME. Circulating Chlamydia pneumoniae DNA as a predictor of coronary artery disease. J Am Coll Cardiol. 1999;34:1435-9.
6. Grayston JT, Campbell LA, O'Brien ER, Cappuccio AL, Kuo CC, Wang SP, et al. Detection of Chlamydia pneumoniae (TWAR) in human atherectomy tissues. J Infect Dis. 1995;172:585-8.
7. Kuo CC, Shor A, Campbell LA, Fukushi H, Patton DL, Grayston JT. Demonstration of Chlamydia pneumoniae in atherosclerotic lesions of coronary arteries. J Infect Dis. 1993;167:841-9.
8. Kuo CC, Gown AM, Benditt EP, Grayston JT. Detection of Chlamydia pneumoniae in aortic lesions of atherosclerosis by immunocytochemical stain. Arterioscler Thromb. 1993;13:1501-4.
9. Libby P. Atheroma: more than mush. Lancet. 1996;348 Suppl 1:4-7.
10. Ross R. Atherosclerosis: an inflammatory disease. N Engl J Med. 1999;340:115-26.
11. Roblin PM, Dumornay W, Hammerschlag MR. Use of Hep-2 cells for improved isolation and passage of Chlamydia pneumoniae. J Clin Microbiol. 1992;30:1968-71.
12. Cuffini C, Becher S, Adamo P, Pedranti M, Zapata M. Producción y caracterización de anticuerpos monoclonales, dirigidos contra la proteína mayor de membrana externa y contra el lipopolisacárido de Chlamydia trachomatis. Rev Arg Microbiol. 2001;33:203-8.
13. Campbell LA, Pérez-Melgosa M, Hamilton DJ, Kuo CC, Grayston JT. Detection of Chlamydia pneumoniae by polymerase chain reaction. J Clin Microbiol. 1992;30:434-9.
14. Cochrane M, Pospischil A, Walker P, Gibbs H, Timms P. Distribution of C. pneumoniae DNA in atherosclerotic carotid arteries: significance for sampling procedures. J Clin Microbiol. 2003;41:1454-7.
15. Hammerschlag MR. Antimicrobial susceptibility and therapy of infections caused by Chlamydia pneumoniae. Antimicrob Agents Chemother. 1994;38:1873-8.
16. Hammerschlag MR, Hyman CL, Roblin PM. In vitro activities of five quinolones against Chlamydia pneumoniae. Antimicrob Agents Chemother. 1992;38:682-3.
17. Linnanmäki E, Leinonen M, Mattila K, Nieminen MS, Valtonen V, Saikku P. Chlamydia pneumoniae-specific circulating immune complexes in patients with chronic coronary heart disease. Circulation. 1993;87:1130-4.
18. Puolakkainen M, Kuo CC, Shor A. Wang SP, Grayston JT, Campbell LA. Serological response to Chlamydia pneumoniae in adults with coronary arterial fatty streaks and fibrolipid plaques. J Clin Microbiol. 1993;31:2212-4.
19. Boman J, Sonderberg S, Forsberg J, Birgander LS, Allard A, Persson K, et al. High prevalence of Chlamydia pneumoniae DNA in peripheral blood mononuclear cells in patients with cardiovascular disease and in middle-aged blood donors. J Infect Dis. 1998;178:274-7.
20. Gaydos CA, Summersgill JT, Sahney NN, Ramírez JA, Quinn TC. Replication of Chlamydia pneumoniae in human macrophages, endothelial cells and aortic artery smooth muscle cells. Infect Immunol. 1996;64:1614-20.
21. Ross R. The pathogenesis of atherosclerosis: a perspective for the 1990's. Nature. 1993;362:801-9.
22. Gieffers J, Füllgraf H, Jahn J, Klinger M, Dalhoff K, Katus HA, et al. C. pneumoniae infection in circulating human monocytes is refractory to antibiotic treatment. Circulation. 2001;103:351.
23. Gurfinkel E, Bozovich G, Daroca A, Beck E, Mautner B. Randomized trial of roxithromycin in non-Q-wave coronary syndromes: ROXIS Pilot Study. Lancet. 1997;350:404-7.
24. Gupta S, Leatham EW, Carrington D, Mendall MA, Kaski JC, Camm AJ. Elevated C. pneumoniae antibodies, cardiovascular events, and azithromycin in male survivors of acute myocardial infarction. Circulation. 1997;96:404-7.
25. Anderson JL, Muhlestein JB, Carlquist J, Allen A, Trehan S, Nielson C, et al. Randomized secondary prevention trial of azithromycin in patients with coronary artery disease and serological evidence for Chlamydia pneumoniae infection: the azithromycin in coronary artery disease: elimination of myocardial infection with Chlamydia (ACADEMIC) study. Circulation. 1999;99:1540-7.
26. Grayston JT. Antibiotic treatment trials for secondary prevention of coronary artery disease events. Circulation. 1999;99:1538-9.
27. Muhlestein JB, Anderson JL, Carlquist JF, Salunkhe K, Home BD, Pearson RR, et al. Randomized secondary prevention trial of azithromycin in patients with coronary artery disease: primary clinical results of the ACADEMIC study. Circulation. 2000;102:1755-60.
28. O'Connor CM, Dunne MW, Pfeffer MA, Muhlestein JB, Yao L, Gupta S, et al. Azithromycin for the secondary prevention of coronary heart disease events: the WIZARD study: a randomized controlled trial. JAMA. 2003;290:1459-66.
29. Cannon CP, Braunwald E, McCabe CH, Grayston JT, Muhlestein B, Giugliano RP, et al. Antibiotic treatment of Chlamydia pneumoniae after acute coronary syndrome. N Engl J Med. 2005;352:1646-54.
30. Neumann FJ, Kastrati A, Miethke T, Pogatsa-Murray G, Mehilli J, Valina C, et al. Treatment of Chlamydia pneumoniae infection with roxithromycin and effect on neointima proliferation after coronary stent placement (ISAR-3): a randomized, double-blind, placebo-controlled trial. Lancet. 2001;357:2085-9.
31. Wiesli P, Czerwenka W, Meniconi A, Maly FE, Hoffmann U, Vetter W, et al. Roxithromycin treatment prevents progression of peripheral arterial occlusive disease in Chlamydia pneumoniae seropositive men. Circulation. 2002;105:2646-52.
32. Krayenbuehl PA, Wiesli P, Maly FE, Vetter W, Schulthess G. Progression of peripheral arterial occlusive disease is associated with Chlamydia pneumoniae seropositivity and can be inhibited by antibiotic treatment. Atherosclerosis. 2005;179:103-10.
33. Shimizu M, Pelisek J, Niko S. Vasculogenesis and angiogenesis depend on the developmental origin in the arterial tree. Curr Med Chem. 2002;9:1619-30.